Sentiment-Signal
15,1
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 30.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointments of Certain Office |
Stammdaten
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Unternehmen & Branche
| Name | Protagonist Therapeutics, Inc |
|---|---|
| Ticker | PTGX |
| CIK | 0001377121 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 6,50 Mrd. USD |
| Beta | 2,11 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -130,149,000 | -2.05 | 668,188,000 | 614,707,000 | |
| 2025-09-30 | 10-Q | -39,339,000 | -0.62 | 701,688,000 | 645,437,000 | |
| 2025-06-30 | 10-Q | -34,771,000 | -0.55 | 718,006,000 | 668,018,000 | |
| 2025-03-31 | 10-Q | -11,655,000 | -0.19 | 742,132,000 | 689,052,000 | |
| 2024-12-31 | 10-K | 275,188,000 | 4.23 | 744,725,000 | 675,295,000 | |
| 2024-09-30 | 10-Q | -33,210,000 | -0.54 | 603,857,000 | 531,915,000 | |
| 2024-06-30 | 10-Q | -30,616,000 | -0.50 | 614,629,000 | 541,324,000 | |
| 2024-03-31 | 10-Q | 207,340,000 | 3.26 | 629,276,000 | 560,444,000 | |
| 2023-12-31 | 10-K | -78,955,000 | -1.39 | 357,951,000 | 336,677,000 | |
| 2023-09-30 | 10-Q | -34,105,000 | -0.58 | 330,016,000 | 302,149,000 | |
| 2023-06-30 | 10-Q | -38,460,000 | -0.68 | 320,466,000 | 294,068,000 | |
| 2023-03-31 | 10-Q | -33,725,000 | -0.67 | 239,858,000 | 216,167,000 | |
| 2022-12-31 | 10-K | -127,393,000 | -2.60 | 247,928,000 | 215,608,000 | |
| 2022-09-30 | 10-Q | -31,232,000 | -0.64 | 282,174,000 | 243,616,000 | |
| 2022-06-30 | 10-Q | -41,037,000 | -0.84 | 310,512,000 | 267,978,000 | |
| 2022-03-31 | 10-Q | -20,930,000 | -0.43 | 348,296,000 | 301,778,000 | |
| 2021-12-31 | 10-K | -125,551,000 | -2.71 | 347,695,000 | 300,021,000 | |
| 2021-09-30 | 10-Q | -33,804,000 | -0.70 | 373,175,000 | 329,660,000 | |
| 2021-06-30 | 10-Q | -30,842,000 | -0.69 | 404,232,000 | 357,447,000 | |
| 2021-03-31 | 10-Q | -23,998,000 | -0.54 | 298,072,000 | 259,334,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-20 | Ali Asif | Officer, Chief Financial Officer | Open Market Sale | -1,750 | 105.47 | -184,572.50 | -14,7% | |
| 2026-03-26 | Ali Asif | Officer, Chief Financial Officer | Open Market Sale | -24,765 | 104.24 | -2,581,503.60 | -205,8% | |
| 2026-03-25 | PATEL DINESH V PH D | Director, Officer, President and CEO | Open Market Sale | -54,641 | 101.00 | -5,518,741.00 | -440,0% | |
| 2026-03-24 | PATEL DINESH V PH D | Director, Officer, President and CEO | Open Market Sale | -59 | 101.00 | -5,959.00 | -0,5% | |
| 2026-02-06 | Waddill William D. | Director | Open Market Sale | -20,000 | 83.68 | -1,673,600.00 | -133,4% | |
| 2026-01-27 | Ali Asif | Officer, Chief Financial Officer | Open Market Sale | -18,203 | 83.14 | -1,513,397.42 | -120,6% | |
| 2026-01-27 | Ali Asif | Officer, Chief Financial Officer | Open Market Sale | -28,000 | 83.13 | -2,327,640.00 | -185,6% | |
| 2026-01-27 | PATEL DINESH V PH D | Director, Officer, President and CEO | Open Market Sale | -4,068 | 83.19 | -338,416.92 | -27,0% | |
| 2026-01-26 | PATEL DINESH V PH D | Director, Officer, President and CEO | Open Market Sale | -14,205 | 84.05 | -1,193,930.25 | -95,2% | |
| 2026-01-26 | PATEL DINESH V PH D | Director, Officer, President and CEO | Open Market Sale | -10,685 | 84.00 | -897,540.00 | -71,6% | |
| 2026-01-23 | PATEL DINESH V PH D | Director, Officer, President and CEO | Open Market Sale | -19,315 | 84.59 | -1,633,855.85 | -130,3% | |
| 2026-01-20 | Ali Asif | Officer, Chief Financial Officer | Open Market Sale | -8,588 | 82.48 | -708,338.24 | -56,5% | |
| 2026-01-20 | PATEL DINESH V PH D | Director, Officer, President and CEO | Open Market Sale | -34,438 | 82.48 | -2,840,446.24 | -226,4% | |
| 2025-10-10 | Waddill William D. | Director | Open Market Sale | -8,000 | 87.81 | -702,480.00 | -56,0% | |
| 2025-10-10 | Waddill William D. | Director | Open Market Sale | -4,000 | 69.25 | -277,000.00 | -22,1% | |
| 2025-09-22 | Waddill William D. | Director | Open Market Sale | -4,000 | 64.25 | -257,000.00 | -20,5% | |
| 2025-08-27 | Waddill William D. | Director | Open Market Sale | -4,000 | 59.25 | -237,000.00 | -18,9% | |
| 2025-07-25 | PATEL DINESH V PH D | Director, Officer, President and CEO | Open Market Sale | -10,415 | 54.78 | -570,533.70 | -45,5% | |
| 2025-07-23 | PATEL DINESH V PH D | Director, Officer, President and CEO | Open Market Sale | -17,520 | 54.79 | -959,920.80 | -76,5% | |
| 2025-07-22 | PATEL DINESH V PH D | Director, Officer, President and CEO | Open Market Sale | -22,065 | 55.05 | -1,214,678.25 | -96,8% | |
| 2025-07-21 | PATEL DINESH V PH D | Director, Officer, President and CEO | Open Market Sale | -12,859 | 54.86 | -705,444.74 | -56,2% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.